In an 84‑year‑old woman with preserved renal function (creatinine 0.49 mg/dL, eGFR >90 mL/min), hemoglobin A1c 14.8 % and weight 59.6 kg who is currently on basal insulin glargine 11 U daily with an insulin‑to‑carbohydrate ratio of 1:15 and an insulin sensitivity factor of 1:50 but refuses insulin at discharge, what non‑insulin treatment options are appropriate?

Non-Insulin Treatment Options for an 84-Year-Old with Severe Hyperglycemia

Given this patient's A1c of 14.8% and preserved renal function, she should be started on combination therapy with metformin plus a GLP-1 receptor agonist (GLP-1 RA), as this represents the most effective non-insulin approach for severe hyperglycemia while minimizing hypoglycemia risk in an older adult. 1

Rationale for This Approach

Why Insulin Can Be Transitioned Off

While current guidelines typically recommend insulin for A1c >10% 1, 2, recent evidence demonstrates that severe hyperglycemia can be effectively treated with non-insulin agents, including GLP-1 RAs, though data is limited for baseline A1c above 10-12% 1. The key principle is that as glucose toxicity resolves with initial treatment, simplification to non-insulin regimens becomes possible 1, 2.

Recommended Treatment Algorithm

Step 1: Initiate Metformin

• Start with 500 mg once or twice daily with meals
• Titrate gradually to minimize GI side effects (bloating, diarrhea) 1
• Extended-release formulation may improve tolerability
• Safe with her eGFR >90 mL/min (metformin is safe down to eGFR ≥30 mL/min/1.73 m²) 1
• Target dose: 1000 mg twice daily or 2000 mg extended-release once daily
• Monitor vitamin B12 levels periodically due to deficiency risk 1

Step 2: Add GLP-1 Receptor Agonist

• This is the critical second agent for her A1c level 1, 2
• GLP-1 RAs typically lower A1c by 0.7-1.0% but can achieve greater reductions with higher baseline A1c 1, 2
• Choose based on:
  • Weekly injectable options (semaglutide, dulaglutide) for convenience in older adults 3
  • Oral semaglutide if injection aversion is severe 3
• Start at lowest dose and titrate slowly to minimize nausea/vomiting 3
• Key advantages for this patient:
  • Minimal hypoglycemia risk (does not cause hypoglycemia as monotherapy) 1
  • Weight neutral to weight loss effect
  • No dose adjustment needed with preserved renal function 4

Alternative or Additional Agents

If GLP-1 RA is not tolerated or contraindicated:

SGLT2 Inhibitors (second-line option)

• Safe and effective with eGFR >30 mL/min 5
• Lower A1c by approximately 0.7-1.0% 5
• Advantages: Cardiovascular and renal benefits, minimal hypoglycemia risk 5, 6
• Cautions in older adults: Risk of volume depletion, genital infections, increased fall risk due to orthostasis 3
• Monitor for dehydration given her age

DPP-4 Inhibitors (third-line option)

• More modest A1c reduction (0.5-0.8%) 7, 8
• Well-tolerated in older adults with minimal side effects
• Most require dose adjustment for renal function (linagliptin does not) 8
• Lower efficacy makes this less ideal for A1c 14.8%

Sulfonylureas (generally avoid)

• While effective for severe hyperglycemia 2, high hypoglycemia risk in older adults 9
• Glyburide should NOT be used in patients ≥65 years 9
• If used, choose agents without active renal metabolites and use lower doses 9, 8

Practical Implementation Strategy

Transition Plan from Insulin

1. Continue current Lantus 11 units while initiating oral agents to prevent rebound hyperglycemia
2. Start metformin with gradual titration over 2-4 weeks
3. Add GLP-1 RA at starting dose with slow titration
4. Reduce insulin by 20-30% every 1-2 weeks as glucose improves 3
5. Discontinue insulin once fasting glucose consistently <150 mg/dL on oral agents

Monitoring Requirements

• Frequent glucose monitoring initially (before meals and bedtime) to guide insulin reduction 3
• Target fasting glucose: 90-150 mg/dL for older adults 3
• Recheck A1c in 3 months 10
• Realistic A1c goal for this patient: 7.5-8.5% given age and complexity 11, 3

Critical Caveats

When This Approach May Fail

• If she has undiagnosed type 1 diabetes or latent autoimmune diabetes, non-insulin therapy will be inadequate
• If catabolic features present (unintentional weight loss, ketosis), insulin remains necessary 1
• GI side effects from GLP-1 RAs may limit tolerability, especially nausea and diarrhea 3

Safety Considerations for Older Adults

• Avoid overaggressive glycemic targets that increase hypoglycemia risk 11, 3
• Assess for frailty, cognitive impairment, and functional status to guide intensity 3, 12
• Simplify regimen to improve adherence 3
• Consider social support and ability to manage medications 3

If Non-Insulin Therapy Proves Insufficient

If A1c remains >9% after 3-6 months on maximized oral therapy, reconsider basal insulin with simplified dosing (once-daily glargine) combined with oral agents, as this may be necessary for durable control 1, 3.